| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10. | Bolt Projects announces prelim Q3 results and updates 2025 guidance | 1 | Seeking Alpha | ||
| 17.10. | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.10. | Bolt Projects Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.09. | Bolt Projects registers 20M shares for potential sale under $20M equity line | 2 | Seeking Alpha | ||
| 26.09. | Bolt Projects Holdings, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| BOLT PROJECTS Aktie jetzt für 0€ handeln | |||||
| 15.09. | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.08. | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08. | Bolt Projects files to sell 913,979 shares of common stock for holders | 1 | Seeking Alpha | ||
| 22.08. | Bolt Projects Holdings, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 15.08. | Bolt Projects to raise $4.25M in private placement | 5 | Seeking Alpha | ||
| 15.08. | Bolt Projects announces $4.25 million private placement | 1 | Investing.com | ||
| 14.08. | Aktie von Bolt Projects bricht nach Kapitalerhöhung mit hohem Abschlag ein | 2 | Investing.com Deutsch | ||
| 14.08. | Bolt Projects stock tumbles after discounted share offering | 12 | Investing.com | ||
| 14.08. | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | 651 | AFX News | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| 14.08. | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.08. | Bolt Projects Holdings Stock Plunges Over 25% In Pre-Market Trading, Day After 557% Surge | 1 | Benzinga.com | ||
| 13.08. | Bolt Projects Stock Surges 38% on Strong Q2, $20M Funding; CEO: 'Demand For Vegan Silk Continues To Grow' | 15 | Benzinga.com | ||
| 12.08. | Bolt Projects Holdings, Inc. - 10-Q, Quarterly Report | 11 | SEC Filings | ||
| 06.08. | Bolt Projects Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.07. | HotStocks USA: +102 % bei Bolt Projects | 13 | stock3.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,114 | +0,57 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| QIAGEN | 40,995 | -0,35 % | QIAGEN N.V.: QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing | QIAcube Connect drives lab efficiency by automating critical steps in molecular biology workflows for both research and clinical customers Milestone builds on nearly 13,000 cumulative placements... ► Artikel lesen | |
| CUREVAC | 4,590 | -0,17 % | Nächster Schritt bei Curevac-Übernahme durch Biontech | MAINZ (dpa-AFX) - Bei der geplanten Übernahme des Tübinger Impfstoff-Entwicklers Curevac durch den Mainzer Konkurrenten Biontech folgt der nächste Schritt. Nach der Zustimmung des Bundeskartellamtes... ► Artikel lesen | |
| VALNEVA | 3,982 | +3,75 % | Valneva-Aktie auf dem Radar - warum viele Investoren plötzlich hellhörig werden! | ||
| NOVAVAX | 7,331 | +0,36 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,930 | -2,01 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma erhält Fast-Track-Status von der US FDA für seinen führenden ADC-Kandidaten HDP-101 zur Behandlung des multiplen Myeloms | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma erhält Fast-Track-Status von der US FDA für seinen führenden ADC-Kandidaten HDP-101 zur Behandlung... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 56,00 | +0,90 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,538 | +2,67 % | Pharma und Biotech im Blockbustermarkt - BioNxt Solutions | In den Industrienationen hat die Häufigkeit von Erkrankungen des Nervensystems in den vergangenen Jahrzehnten kontinuierlich zugenommen. Zu den Hauptursachen gehören das steigende Durchschnittsalter... ► Artikel lesen | |
| OCUGEN | 1,310 | -0,83 % | Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results | ||
| MAINZ BIOMED | 1,580 | +0,64 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed to Attend 2025 Maxim Growth Summit | Issuer: Mainz BioMed N.V.
/ Key word(s): Conference
Mainz Biomed to Attend 2025 Maxim Growth Summit
15.10.2025 / 15:01 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| INFLARX | 1,279 | -1,24 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 12,280 | +2,80 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 75,50 | +1,34 % | Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine | ||
| VIVORYON THERAPEUTICS | 1,624 | -0,61 % | Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE... ► Artikel lesen |